科研之友
微信
新浪微博
Facebook
分享链接
摘要
In order to investigate the anti-tumor angiogenesis activity with a recombinant Ag43/FGFR1 chimeric protein (AF) vaccine in a mouse H22 hepatoma model, tumor volume and survival rate of the mice were studied at a 3-day interval. Microvessel density (MVD) was detected by immunohistochemistry. The endothelial deposition of autoantibodies within tumor tissues was examined by immunofluorescent staining, and anti-FGFR1 antibody-producing B cells (APBCs) were tested by enzyme-linked immunospot (ELISPOT) assay. Compared with the three control groups, the tumor volume was significantly decreased and the survival time was significantly prolonged in AF-immunized group (P < 0.05). The number of APBCs in AF-immunized mice (129.6 +/- 10.9) was more than in controls [6.2 +/- 1.1 (FGFR1), 6.0 +/- 1.2 (Ag43) and 5.2 +/- 1.4 (NS), P < 0.01]. Moreover, the endothelial deposition of autoantibodies was found in tumor tissues from AF-immunized mice, but not in control groups. MVD in AF-immunized group was significantly lower than in FGFR1-immunized group, Ag43-immunized group and NS group (10.3 +/- 3.1 vs 39.4 +/- 8.6 vs 42.3 +/- 9.8 and 43.6 +/- 10.6, P < 0.01). These findings demonstrated that the AF protein vaccine effectively inhibited tumor angiogenesis and growth via production of autoantibodies against self-FGFR1.
